Drug Trial Radar · NCT05005403
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
694
Planned (sponsor's estimate)
Start
Nov 1, 2021
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide. Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Non-Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Micro Satellite Stable Colorectal Cancer
- Gastric/Esophageal Cancer
- High-Grade Serous Ovarian Cancer
- Pancreatic Cancer
- Triple Negative Breast Cancer
Interventions
AzirkitugDrug
Intravenous (IV) Infusion
BudigalimabDrug
Intravenous (IV) Infusion
BevacizumabDrug
Intravenous (IV) Infusion
Telisotuzumab AdizutecanDrug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)Time frame: Up to 2 Years
- Maximum Observed Serum Concentration (Cmax) of AzirkitugTime frame: Up to 2 Years
- Time to Maximum Observed Serum Concentration (Tmax) of AzirkitugTime frame: Up to 2 Years
- Terminal Elimination Half-Life (t1/2) of AzirkitugTime frame: Up to 2 Years
- Area Under the Serum Concentration Versus Time Curve (AUC) of AzirkitugTime frame: Up to 2 Years
- Azirkitug Antidrug Antibody (ADA)Time frame: Up to 2 Years
- Azirkitug Neutralizing Antidrug Antibody (nADA)Time frame: Up to 2 Years
- Cmax of BudigalimabTime frame: Up to 2 Years
- Tmax of BudigalimabTime frame: Up to 2 Years
- t1/2 of BudigalimabTime frame: Up to 2 Years
- AUC of BudigalimabTime frame: Up to 2 Years
- Budigalimab ADATime frame: Up to 2 Years
- Budigalimab nADATime frame: Up to 2 Years
- Cmax of Telisotuzumab AdizutecanTime frame: Up to 2 Years
- Tmax of Telisotuzumab AdizutecanTime frame: Up to 2 Years
- t1/2 of Telisotuzumab AdizutecanTime frame: Up to 2 Years
- AUC of Telisotuzumab AdizutecanTime frame: Up to 2 Years
- Telisotuzumab Adizutecan ADATime frame: Up to 2 Years
- Telisotuzumab Adizutecan nADATime frame: Up to 2 Years
Locations
48 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 276272
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589
Irvine, California · Recruiting
USC Norris Comprehensive Cancer Center /ID# 279603
Los Angeles, California · Recruiting
University of Illinois Hospital and Health Sciences System /ID# 251750
Chicago, Illinois · Recruiting
University of Chicago Medical Center /ID# 276271
Chicago, Illinois · Recruiting
Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593
Fort Wayne, Indiana · Recruiting
Community Health Network, Inc. /ID# 243011
Indianapolis, Indiana · Recruiting
Norton Cancer Institute /ID# 248903
Louisville, Kentucky · Recruiting
START Midwest /ID# 248685
Grand Rapids, Michigan · Recruiting
M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200
Minneapolis, Minnesota · Recruiting
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399
Omaha, Nebraska · Recruiting
Duke Cancer Institute /ID# 276267
Durham, North Carolina · Recruiting
Carolina BioOncology Institute /ID# 232597
Huntersville, North Carolina · Recruiting
NEXT Oncology Austin /ID# 243005
Austin, Texas · Recruiting
The University of Texas MD Anderson Cancer Center /ID# 270059
Houston, Texas · Recruiting
Next Oncology Dallas /ID# 276254
Irving, Texas · Recruiting
NEXT Oncology /ID# 243007
San Antonio, Texas · Recruiting
South Texas Accelerated Research Therapeutics (START) /ID# 276268
San Antonio, Texas · Recruiting
Start Mountain Region /ID# 276270
West Valley City, Utah · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 232592
Fairfax, Virginia · Recruiting
Tom Baker Cancer Centre /ID# 276206
Calgary, Alberta, Canada · Recruiting
Princess Margaret Cancer Centre /ID# 276275
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 276274
Montreal, Quebec, Canada · Recruiting
Rambam Health Care Campus /ID# 238333
Haifa, Israel · Recruiting
Shaare Zedek Medical Center /ID# 276244
Jerusalem, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 252287
Jerusalem, Israel · Recruiting
Shamir Medical Center /ID# 276238
Beer Ya'akov, Central District, Israel · Recruiting
Meir Medical Center /ID# 277327
Kefar Sava, Central District, Israel · Recruiting
Rabin Medical Center. /ID# 250497
Petah Tikva, Central District, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 238332
Ramat Gan, Tel Aviv, Israel · Recruiting
Tel Aviv Sourasky Medical Center /ID# 276591
Tel Aviv, Tel Aviv, Israel · Recruiting
Aichi Cancer Center Hospital /ID# 250405
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East /ID# 238840
Kashiwa-shi, Chiba, Japan · Recruiting
Kobe University Hospital /ID# 250409
Kobe, Hyōgo, Japan · Recruiting
Kansai Medical University Hospital /ID# 276805
Hirakata-shi, Osaka, Japan · Recruiting
Shizuoka Cancer Center /ID# 250408
Sunto-gun, Shizuoka, Japan · Recruiting
National Cancer Center Hospital /ID# 238372
Chuo-ku, Tokyo, Japan · Recruiting
Wakayama Medical University Hospital /ID# 276806
Wakayama, Wakayama, Japan · Completed
National Cancer Center /ID# 252290
Goyang-si, Gyeonggido, South Korea · Recruiting
CHA Bundang Medical Center /ID# 252291
Seongnam, Gyeonggido, South Korea · Recruiting
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.